Thomas Deal
Stock Analyst at Raymond James
(1.24)
# 3,782
Out of 5,189 analysts
6
Total ratings
66.7%
Success rate
-8.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Deal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Reiterated: Buy | $140 → $144 | $115.31 | +24.88% | 3 | Oct 29, 2026 | |
| NKTR Nektar Therapeutics | Initiated Coverage: Hold | n/a | $30.20 | - | 1 | Oct 8, 2026 | |
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | $42 | $16.96 | +147.64% | 1 | Oct 8, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $6 | $0.8399 | +614.37% | 1 | Oct 8, 2026 |
Kymera Therapeutics
Oct 29, 2026
Reiterated: Buy
Price Target: $140 → $144
Current: $115.31
Upside: +24.88%
Nektar Therapeutics
Oct 8, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $30.20
Upside: -
Odyssey Therapeutics
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $16.96
Upside: +147.64%
Palisade Bio
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $0.8399
Upside: +614.37%